Purpose: Although members of the galectin family of carbohydrate-binding proteins are thought to play a role in the immune response and regulation of allograft survival, little is known about the galectin expression signature in failed corneal grafts. The aim of this study was to compare the galectin expression pattern in accepted and rejected murine corneal allografts.
C
orneal transplantation is the most common form of solid organ transplantation, comprising more than 40,000 surgical procedures annually in the United States alone. 1 Due to the immune privilege and avascularity of normal corneas, corneal allograft survival rates are commonly as high as 90%. 2 However, preoperative risk factors such as corneal vascularization, ocular surface disease, or multiple prior graft failure can markedly increase the rejection rate to 50% to 90%. 3, 4 The mechanism of corneal allograft rejection involves both innate and adaptive immunity, and it comprises 3 steps: (1) antigen-presenting cells such as dendritic cells and macrophages migrate to the draining lymph nodes through the lymphatic vessels, (2) antigen-presenting cells prime the T cells in the lymph nodes and the activated T cells undergo clonal expansion, and (3) the activated T cells enter the bloodstream and return to the cornea to attack allografts (reviewed in Niederkorn and Larkin 5 and Skobe and Dana 6 ). Strategies to block one or more of these 3 steps can increase the survival rate of the corneal allografts.
Galectins are a family of animal lectins capable of recognizing b-galactosides. 7, 8 Galectins are important modulators of immune response as cells of the innate and adaptive immune system both express galectins 9 and these galectins can be either antiinflammatory or proinflammatory. 10, 11 In general, both galectins-1 and 9 are considered antiinflammatory galectins, whereas galectin-3 is viewed as a proinflammatory galectin. Functions of neutrophils and macrophages are inhibited by galectins-1 and 9 but are promoted by galectin-3. Both galectins-1 and 9 treatment promote regulatory T (Treg)-cell polarization, whereas galectin-3 plays a negative role in Treg cell expansion (reviewed in Liu and Rabinovich and Rabinovich and Toscano). 11, 12 More recently, galectins have been shown to modulate angiogenic responses as galectins-1, 3, and 8 are proangiogenic, [13] [14] [15] whereas galectin-9 is anti-angiogenic. 16 Recent studies demonstrate the critical importance of several members of the galectin family for graft survival.
Nonocular studies have shown that (1) galectin-1 has antiinflammatory effects and promotes immunologic tolerance of renal allografts in rats and liver allografts in mice 17, 18 and (2) galectin-9 promotes an immunosuppressive environment and prolongs the survival of liver allografts in rats, and cardiac and skin allografts in mice. [19] [20] [21] [22] In addition, the expression level of galectin-7 is markedly elevated in renal allografts undergoing acute rejection episodes. 23 So far, only 1 report has demonstrated the involvement of galectins in the survival of corneal allografts, as graft survival in mice treated with an anti-galectin-9 neutralizing antibody is significantly reduced and as Tim-3-galectin-9 interactions assist to establish the immune privilege of these grafts. 24 However, other than galectin-9, virtually nothing is known about the role of galectins in corneal allografts.
Despite such major interest in the functions of galectins, their expression pattern in the context of corneal transplantation has thus far not been elucidated. In this study, we seek to compare the expression levels and distribution of galectins in mouse corneas with accepted and rejected allografts.
MATERIALS AND METHODS

Reagents and Antibodies
The specific reagents included the following: Odyssey blocking buffer (OBB) from Li-Cor Biosciences (Lincoln, NE); goat anti-mouse galectin-1 from R&D Systems (Minneapolis, MN); a hybridoma secreting rat anti-human/mouse galectin-3 (mAb M3/38) from ATCC (Manassas, VA); rabbit anti-mouse galectin-7 from Bethyl Laboratories (Montgomery, TX); rabbit anti-human/mouse galectin-8 from Novus Biologicals (Littleton, CO); rat anti-mouse galectin-9 (clone 108A2) from BioLegend (San Diego, CA); anti-b-actin (clone AC-15) from Santa Cruz Biotechnology (Dallas, TX). Infrared secondary antibodies obtained from Li-Cor were as follows: donkey anti-goat immunoglobulin G (IgG) IRDye 800CW, donkey anti-rabbit IgG IRDye 680LT, goat anti-rat IgG IRDye 800CW, goat anti-rabbit IgG IRDye 680LT, and goat anti-mouse IgG IRDye 680LT. Fluorescence-labeled secondary antibodies purchased from Life technologies (Grand Island, NY) were the following: Alexa Fluor 488-conjugated anti-rat IgG, Alexa Fluor 568-conjugated anti-rabbit IgG, and Alexa Fluor 488-conjugated anti-goat IgG.
Animals
BALB/c (male, 8-10 weeks old) and C57BL/6 (male, 6 weeks old) mice were obtained from Jackson Laboratory (Bar Harbor, ME). All experimental procedures were conducted in compliance with the Association for Research in Vision and Ophthalmology statement for the use of animals in ophthalmic and visual research and were approved by the Institutional Animal Care and Use Committee at Tufts University.
Corneal Transplantation
BALB/c mice were used as graft recipients and C57BL/6 mice were used as donors. For preparation of donor corneas, mice were anesthetized by intramuscular injections with ketamine (125 mg/kg) and xylazine (8.5 mg/kg). To prevent iris damage, pupils were preoperatively dilated with tropicamide ophthalmic solution (1%; Akorn, Lake Forest, IL). Tetracaine ophthalmic solution (0.5%; Alcon Laboratories, Fort Worth, TX) was used as topical anesthetic. The donor corneas were marked with a 2.0-mm trephine, excised with Vannas scissors, and placed in phosphate-buffered saline (PBS, pH7.4). Viscoelastic (Provisc; Alcon Laboratories) was used intracamerally to protect the donor corneal endothelium, as the donor corneal discs were sutured into similarly prepared 1.5-mm-diameter corneal beds of BALB/c mice recipients with 8 to 10 interrupted sutures (11-0 nylon; Surgical Specialties, Reading, PA). At the conclusion of the surgery, the viscoelastic material was exchanged for PBS, Neomycin and polymyxin B sulfates and Bacitracin Zinc ophthalmic Ointment USP (Akorn) were topically applied, and a single eyelid suture (8-0 nylon; Surgical Specialties) was performed. Both eyelid and corneal sutures were removed 1 week after surgery. All mice were killed on postoperative week 4, and the enucleated eyes were used for Western blot analyses and immunofluorescence staining.
The procedures involving syngeneic graft controls (n = 11) were the same except that donor corneas from BALB/c mice were used.
Evaluation and Scoring of Mouse Corneal Allografts
Grafts were evaluated for signs of rejection by slit-lamp biomicroscopy (SL-D7; Topcon, Tokyo, Japan) once per week for 4 weeks by a single observer. A previously reported scoring system 25 was used to grade the degree of corneal clarity, ranging from 0 to 5+ (0, clear graft; 1+, minimal superficial opacity; 2+, mild stromal opacity with pupil margin and iris vessels visible; 3+, moderate stromal opacity with only pupil visible; 4+, intense stromal opacity with the anterior chamber visible; 5+, severe stromal opacity with total obscuration of the anterior chamber). Grafts with an opacity score of 3+ or greater on postoperative week 4 were considered rejected; grafts with opacity scores of 3+ or greater on postoperative week 2, which never cleared, were also considered rejected.
Selection of Galectins
In a recent study (Chen et al, submitted), we have established that of the 15 known galectins, only 5 galectins, galectins-1, 3, 7, 8, and 9, are relevant to corneal diseases. Therefore, for the current study, the specific expression patterns of these 5 galectins were examined.
Western Blot Analysis
Protein extracts of mouse corneas were prepared in a radioimmunoprecipitation buffer supplemented with a protease inhibitor cocktail (cOmplete tablets; Roche Applied Science, Mannheim, Germany) and 2% sodium dodecyl sulfate. Four or more corneas from the accepted or the rejected groups were pooled and considered one biological replica. Aliquots of lysates containing 30 mg of proteins were subjected to electrophoresis in 4% to 15% sodium dodecyl sulfatepolyacrylamide gel electrophoresis gels (Bio-Rad, Hercules, CA). Protein blots of the gels were blocked with OBB and incubated with goat anti-galectin-1 (1:1000) and rabbit antigalectin-8 (1:750) primary antibodies in OBB (overnight, 4°C). The secondary antibodies used were anti-goat IgG 800CW and anti-rabbit IgG 680LT diluted in OBB (1:10,000, 45 minutes, 25°C). Blots were then scanned with the Odyssey Infrared Imaging System using Image Studio v2.0 software (Li-COR). After image acquisition, the blots were stripped using the NewBlot nitrocellulose stripping buffer (Li-COR) and reprobed using rabbit anti-galectin-7 (1:10,000) and rat antigalectin-9 (1:1000) as primary antibodies. The secondary antibodies used were anti-rat IgG 800CW and anti-rabbit IgG 680LT. After image acquisition, the blots were stripped again and reprobed with rat anti-galectin-3 (1:5000) and mouse antib-actin (1:10,000) as primary antibodies, and anti-rat IgG 800CW and anti-mouse IgG 680LT as secondary antibodies. Relative band intensity was quantified by Image Studio v2.0 software. For total corneal extracts, data were normalized to b-actin expression. We have previously tested each antigalectin antibody used in the current study for specificity against recombinant human galectins-1, 3, 7, 8, and 9 by the Western blot analysis (Chen et al, submitted) and have shown that the antibodies against galectins-1, 3, 7, and 8 do not crossreact with any other galectins examined. According to the product datasheet, the anti-mouse galectin-9 antibody does not cross-react with human galectin-9.
Immunofluorescence Staining
Frozen sections of the eyes were fixed with iced acetone (10 minutes, 25°C), blocked with Image-iT FX signal enhancer (30 minutes, 25°C; Life Technologies), and immunostained using anti-galectin primary antibodies (1:100 dilution in 5% bovine serum albumin/PBS, overnight, 4°C), as described in the previous section for Western blot analyses, and Alexa Fluor 488-conjugated anti-rat, Alexa Fluor 568-conjugated antirabbit or Alexa Fluor 488-conjugated anti-goat secondary antibodies (1:300 dilution in 5% bovine serum albumin/PBS, 1 hour, 25°C). Negative controls with no applied primary antibody were also used. Fluorescence images were acquired by Leica TCS SPE imaging system (Leica).
Statistics
Data were analyzed using an unpaired 2-tailed Student t test in Prism 6 (GraphPad). P , 0.05 was considered statistically significant.
RESULTS
Graft Survival Rate of Corneal Allografts
Normal risk corneal transplantation (graft donors: C57BL/6 mice; graft recipients: BALB/c mice) was successfully performed in 57 eyes, defined as opacity score 0 on postoperative week 1. Grafts on postoperative week 2 with corneal opacity scores of 3 or more, which never cleared, were considered rejected; and grafts on postoperative week 4 with corneal opacity scores of 3 or more were also considered rejected. Representative photographs of the rejected (opacity score 5) and accepted (opacity score 1) allografts on postoperative week 4 are shown in Figure 1A . Graft survival rate was 75% (43 of 57) on postoperative week 2, 44% (25 of 57) on postoperative week 3, and 26% (15 of 57) on postoperative week 4 (Fig. 1B) . Survival rate of syngeneic grafts was 100% on postoperative week 4 (n = 11, data not shown).
Expression Pattern of Galectins in Accepted and Rejected Corneal Allografts
On postoperative week 4, accepted and rejected corneal allografts were collected and analyzed separately. As a control, corneal discs marked with a 2-mm trephine and excised from normal C57BL/6 mice were mixed at a ratio of 1:1 with corneas from normal BALB/c mice without the central corneal regions. Fold-change values relative to b-actin expression of various galectins are shown in Figure 2 . Expression levels of all 5 galectins in both rejected and accepted corneal allografts were significantly increased compared with controls. There were distinct differences in the expression levels of galectins-8 and 9 between the accepted and rejected grafts, as galectin-8 expression level in the rejected corneal allografts was markedly higher (26.8-fold) than in the accepted (9.0-fold) corneal allografts (Fig. 2) . Conversely, galectin-9 expression level in the rejected corneal allografts was substantially lower (2.5-fold) compared with the accepted (11.5-fold) corneal allografts (Fig. 2) . Expression levels of galectins-1, 3 and 7 exhibited no significant differences between the rejected and accepted corneal allografts (Fig. 2) .
Immunofluorescence Localization of Galectins in Accepted and Rejected Corneal Allografts
To investigate the galectin expression pattern at the tissue level, frozen sections from normal corneas and corneas with accepted and rejected allografts on postoperative week 4 (n = 3 each) were immunostained with anti-galectin antibodies. In normal corneas, galectin-1 was mainly expressed in the corneal stroma; galectin-3 was mainly expressed in the corneal epithelium, and galectins-7, 8, and 9 were expressed in both corneal stroma and epithelium (Fig. 3) . Galectin-9 immunoreactivity in the normal corneal stroma was visible but at a much reduced intensity compared with that in the normal epithelium. In both rejected and accepted allografts, immunoreactivity of all 5 lectins was stronger compared with the control. In addition, consistent with the results of the Western blot analysis, compared with the accepted grafts, there was an increased galectin-8 immunoreactivity and a decreased galectin-9 immunoreactivity in the rejected grafts. In addition, similar results were obtained when the tissue sections were stained with an immunoperoxidase-based chromogenic detection system (data not shown). In addition, galectin-3 immunoreactivity in the donor stroma was stronger in the rejected grafts, whereas galectin-9 immunoreactivity in the recipient stroma was stronger in the accepted grafts (Fig. 3) .
DISCUSSION
In this study, we demonstrate that the rejected corneal allografts have a higher galectin-8 and a lower galectin-9 protein expression compared with the accepted corneal Lysates of whole corneas containing 30 mg of protein were subjected to electrophoresis in 4% to 15% sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels. Protein blots of the gels were probed using anti-galectin antibodies as described in Materials and Methods. A, Representative immunoblots. B, Relative band intensity was quantified by Image Studio. Expression value of each galectin was normalized to b-actin. A value of 1.0 was given to the expression of each galectin in the normal cornea, and the expression values of galectins in the rejected and accepted allografts were calculated as fold changes with respect to the cornea treated as control. Four or more corneas were pooled and considered 1 biological replica; n = 4. Data are plotted as mean 6 SEM and analyzed using Student t test. *P , 0.05, **P , 0.01, ***P , 0.001.
allografts. To our knowledge, this is the first study examining the galectin expression signature of mouse corneal allografts.
It has been reported that galectin-9 plays an immunosuppressive role in corneal allografts. 24 Consistent with this notion, we observed that galectin-9 expression is higher in the accepted corneal allografts than in the rejected corneal allografts. The upregulation of galectin-9 may dampen the inflammation in the corneal allografts by promoting Treg cell polarization 26 and impairing the functions of natural killer cells, 27 which are also involved in corneal allograft rejection. 28 Notably, in the corneas treated as controls, galectin-9 is mainly expressed in the epithelium. It has been reported that although the corneal epithelium expresses more than 90% of the major histocompatibility complex antigens, removal of this epithelium does not enhance corneal graft survival in humans and even appears to exacerbate corneal allograft rejection in mice, [29] [30] [31] suggesting that the corneal epithelium suppresses inflammation and neovascularization in corneal allografts. In fact, recent studies have shown that nonvascular vascular endothelial growth factor receptor 3 (VEGFR-3) and alternatively spliced VEGF receptor variants including soluble VEGFR-1, 2, and 3 expressed in the corneal epithelium FIGURE 3. Immunofluorescence localization of galectins in normal corneas and corneas with rejected and accepted allografts. Frozen tissue sections were immunostained using antibodies against galectins-1, 3, 7, 8, and 9, and Alexa fluor 488-conjugated antigoat (for galectin-1, green), Alexa fluor 488-conjugated anti-rat (for galectins-3 and 9, green) and Alexa fluor 568-conjugated anti-rabbit (for galectins-7 and 8, red), followed by counterstaining with DAPI (blue). White arrows indicate the interface between the donor (D) and recipient (R). Immunostaining processing and exposure time of images in rejected and accepted allografts were the same. Note that in normal corneas, galectin-1 is expressed mainly in the corneal stroma, galectin-3 is expressed mainly in the corneal epithelium, and galectins-7, 8 and 9 are present in both epithelium and stroma. In both the rejected and accepted allografts, immunoreactivity of the 5 lectins is detected in both corneal epithelium and stroma. No immunoreactivity was detected in the corneas treated as controls that were treated the same way as the experimental group except that isotype control IgG was used as primary antibody or the step involving incubation with the primary antibody was omitted (negative control, data not shown); n = 3 for each galectin. Bar = 50 mm.
are key in maintaining the angiogenic and/or immune privilege status of the cornea. [32] [33] [34] [35] The molecular mechanism by which galectin-9 exerts its antiinflammatory function in the corneal epithelium is still unclear. Further investigation using mice with corneal epithelium-specific deficiency of galectin-9 may establish its role in corneal allograft survival. Regardless, our findings that galectin-9 expression is reduced in rejected grafts, and previous studies showing that galectin-9 is antiinflammatory (reviewed in Wiersma et al 36 ) and that anti-galectin-9 antibody treatment reduces corneal allograft survival, 24 are consistent with the suggestion that exogenous galectin-9 treatment may be expected to promote corneal allograft survival.
Interestingly, there was no difference in the expression of galectin-1, another antiinflammatory galectin, and galectin-3, a proinflammatory galectin, between the accepted and rejected corneal allografts. However, compared with the normal corneas, the expression of galectins-1 and 3 was higher in both accepted and rejected grafts, possibly suggesting that these 2 lectins may be upregulated in response to the trauma of the surgical procedure. Considering that exogenous galectin-1 inhibits acute and chronic inflammation in Pseudomonas aeruginosa-mediated corneal infection, 37 in herpes simplex virus-mediated corneal infection 38 and in experimental colitis, 39 and that it promotes Treg cell polarization, it is reasonable to propose that exogenous galectin-1 treatment may also prolong corneal allograft survival. On the other hand, given that galectin-3 deficiency attenuates atherosclerosis, 40 which is considered a chronic inflammatory disease, 41 and that higher frequency of Treg cells is observed in galectin-3 knockout mice, 42 it seems likely that inhibiting galectin-3 may increase corneal allograft survival.
The role of galectins-7 and 8 in immunity has thus far not been well characterized. On the one hand, galectin-8 promotes apoptosis of activated peripheral blood mononuclear cells, which may interfere with T-cell expansion. 43 On the other hand, it promotes proliferation and costimulation of naive T cells, which may promote inflammation. 43 To identify the role of galectin-8 in the context of corneal immunity and allograft survival, it will be important to investigate the effect of galectin-8 on different T-cell subpopulations including Th1, Th2, Th17, and Treg cells. Nevertheless, our finding that the expression of galectin-8 is higher in the rejected allografts than in the accepted allografts suggests that galectin-8 may promote inflammation and hence rejection. As galectin-8 stimulates the endothelial cells to produce several inflammatory cytokines including CXCL1, CXCL3, GM-CSF, IL-6, RANTES, and MCP1, 44 it can be hypothesized that galectin-8 acts on the endothelial cells of the newly-grown vessels, but not directly on the immune cells, to promote inflammation in corneal allografts.
As previously noted, immune cells exit the cornea toward draining lymph nodes through the lymphatic vessels and enter the corneal allografts through the blood vessels. Blocking angiogenesis and/or lymphangiogenesis have been proven to increase the corneal allograft survival rates (reviewed in Skobe and Dana 6 ). Recent studies demonstrate that galectins-1 and 3 promote angiogenesis through modulating the functions of some key angiogenic molecules including VEGFR-2 and integrins, and that galectin-8 provokes angiogenesis through CD166 and, more likely, integrins (reviewed in Thijssen et al 45 ). Conversely, galectin-9 reduces angiogenesis in the chick chorioallantoic membrane assay, 16 and exogenous galectin-9 treatment decreases herpes simplex virus-induced corneal angiogenesis. 46 Although the interaction between galectin-9 and Tim-3 is involved in resolving herpes simplex virus-induced corneal pathology including angiogenesis, Tim-3 is not reported to be expressed in the endothelial cells. Therefore, the molecules that bind galectin-9 in the endothelial cells to inhibit angiogenesis are yet to be identified.
In conclusion, our findings of higher galectin-8 expression and lower galectin-9 expression in rejected corneal allografts and published studies demonstrating the roles of galectin-8 in promoting angiogenesis and of galectin-9 in inhibiting angiogenesis and promoting Treg cell polarization, lead us to propose that treatment with exogenous recombinant galectin-9 and/or inhibiting galectin-8 with siRNA or blocking antibody through subconjunctival injections may prolong corneal allograft survival. In addition, considering the known capability of galectins-1 and 3 in suppressing and promoting inflammation, respectively, and despite our equivocal findings in this regard, it remains possible that treatment with exogenous galectin-1 and/or inhibition of galectin-3 might also promote corneal allograft survival. We hope that such studies will provide impetus for in-depth investigation of the actions of galectins in corneal allograft immunology and their potential clinical implications.
